Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/22/2003WO2003041653A2 Cytotoxic agents
05/22/2003WO2003041651A2 Allatoin-containing skin cream
05/22/2003WO2003041649A2 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003WO2003041648A2 High-concentration lidocaine compositions and methods for their preparation
05/22/2003WO2003041647A2 Synthesis and purification of valacyclovir
05/22/2003WO2003041646A2 L-dopa ethyl ester salts and uses thereof
05/22/2003WO2003041645A2 Method of vaccinating a human patient to prevent metastatic tumors
05/22/2003WO2003041644A2 Method to treat cystic fibrosis
05/22/2003WO2003041643A2 Hsp90-inhibiting zearalanol compounds and methods of producing and using same
05/22/2003WO2003041642A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems
05/22/2003WO2003041641A2 Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
05/22/2003WO2003041639A2 Methods and compositions for treating rotavirus-mediated disease
05/22/2003WO2003041638A2 Suppository base
05/22/2003WO2003041632A2 Eutectic-based self-nanoemulsified drug delivery system
05/22/2003WO2003041564A2 Method for effecting hemostasis
05/22/2003WO2003041563A2 Neurotransmitter balance chemotherapy
05/22/2003WO2003028646A3 Methods of treating drug-resistant bacterial infections
05/22/2003WO2003027317A3 Use of active substances for the prophylaxis and/or treatment of diseases caused by cell growth disturbances and test system for discovery of said active substances
05/22/2003WO2003022280A3 3-glyoxlylamideindoles for treating cancer
05/22/2003WO2003020732A3 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors.
05/22/2003WO2003020253A3 Pharmaceutical compositions for the treatment of asthma
05/22/2003WO2003018004A3 Analgetic pyrroline derivatives
05/22/2003WO2003016464A3 Cancer specific oligosaccharide sequences and use thereof
05/22/2003WO2003015695A3 Canine cardiac diet
05/22/2003WO2003013498A3 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
05/22/2003WO2003011277A3 Methods to mobilize progenitor/stem cells
05/22/2003WO2003009775A3 Method for reducing myocardial cell damage by regional beta blocker therapy
05/22/2003WO2003008016A3 Mating insertion instruments for spinal implants and methods of use
05/22/2003WO2003007883A3 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
05/22/2003WO2002100353A3 Cd10-activated prodrug compounds
05/22/2003WO2002100350A3 Dopamine receptor ligands and therapeutic methods based thereon
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002096362A3 Method for treating fibrotic diseases or other indications vi
05/22/2003WO2002089802A3 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/22/2003WO2002085886A3 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
05/22/2003WO2002083120A3 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
05/22/2003WO2002078709A3 Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
05/22/2003WO2002076390A3 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
05/22/2003WO2002072059A3 Topical composition comprising a functionally alkylating cosmetic bonding agent
05/22/2003WO2002072007A3 Facially amphiphilic polymers as anti-infective agents
05/22/2003WO2002060419A3 A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
05/22/2003WO2002059369A3 Compositions and methods for the treatment of diseases related to faulty cholesterol regulation
05/22/2003WO2002056912A3 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
05/22/2003WO2002053740A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/22/2003WO2002053186A3 Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
05/22/2003WO2002053141A3 Inhibition of angiogenesis by nucleic acids
05/22/2003WO2002045749A8 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002043719A3 Composition and method for treating snoring
05/22/2003WO2002043653B1 Crystalline glucosamine sulphate metal salts
05/22/2003WO2002041891A3 Hiv treatment with benzimidazoles
05/22/2003WO2002041879A3 Antidiabetic compositions containing a biguanide and a sulfonamide
05/22/2003WO2002039958A9 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003WO2002024187A3 Treatment of diseases with adamantane derivatives
05/22/2003WO2002024176A3 Treatment of tinnitus
05/22/2003WO2002024146A3 Methods of decreasing or preventing pain using spicamycin derivatives
05/22/2003WO2002022807A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof
05/22/2003WO2001070941A9 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
05/22/2003WO2000037429A3 INHIBITORS OF α4β1 MEDIATED CELL ADHESION
05/22/2003US20030097671 Inhibition of betaarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
05/22/2003US20030097665 To produce phosphorylated lysosomal proteins which are incorporated into pharmaceutical formulations for use in enzyme replacement therapy
05/22/2003US20030097023 For prophylaxis and therapy of immunological diseases, asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia
05/22/2003US20030097018 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030097000 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof
05/22/2003US20030096998 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections
05/22/2003US20030096985 Small and cysteine rich antifungal defensin and thionin-like protein genes highly expressed in the incompatible interaction
05/22/2003US20030096982 Nucleotide sequences coding polypeptide for use in the treatment of immunological, reproductive and liver disorders
05/22/2003US20030096874 For prophylaxis and therapy of respiratory diseases asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease
05/22/2003US20030096873 Administering therapeutically effective amount of (+)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-)-stereoisomer for therapy of pain
05/22/2003US20030096872 Acetaminophen compositions
05/22/2003US20030096871 Reduction of hair growth
05/22/2003US20030096870 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
05/22/2003US20030096869 Locating an artery which carries major blood supply to the tumor; intra-arterially injecting into the located artery a predetermined quantity of a polyunsaturated fatty acid solution and anti-antiogenic substances
05/22/2003US20030096868 Sertraline oral concentrate
05/22/2003US20030096867 To increase the HDL (High density lipoproteins) cholesterol level in blood for prophylaxis of arteriosclerosis
05/22/2003US20030096866 Methods for activating lipid catabolism and improving lipid metabolism in small intestinal epithelium
05/22/2003US20030096865 Composition for improving sleep quality and efficiency , and methods of preparing and using the composition
05/22/2003US20030096863 Method for inhibition or treatment of colon tumorigenesis
05/22/2003US20030096862 Stable NO-delivering compounds
05/22/2003US20030096861 Producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from aqueous solution and dissolving magma into a salting-in mixture to form semitransparent colloidal solution
05/22/2003US20030096860 Benzopyran derivative and antiallergic agent
05/22/2003US20030096859 Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096857 Novel antidiabetic agents
05/22/2003US20030096855 Administering phytochemical Diindolylmethane for therapy of human papilloma virus infection
05/22/2003US20030096854 Substituted tricyclics
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096851 Medicament
05/22/2003US20030096850 Treating infections by administration of oxazolidinones
05/22/2003US20030096845 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096843 Preventives/remedies for kidney diseases
05/22/2003US20030096842 Inhibitors of farnesyl protein transferase
05/22/2003US20030096841 For treatment of cancers, heart disease, such as congestive heart failure, osteoporosis, genetic, inflammatory, allergic, and autoimmune diseases
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096839 Methods for preparing pharmaceutical formulations
1 ... 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 5471 5472 5473 5474 5475 5476 5477 5478 5479 ... 7860